Group contends CMS is promoting a less expensive generic substitute.
The Centers for Medicare and Medicaid Services' decision not to provide insurance coverage for Bidil (isosorbide dinitrate/hydralazine, Nitromed) when it is the only drug approved to treat African Americans with heart failure is racially insensitive. So contends the Washington Legal Foundation (WLF), a public interest law and policy center. So WLF has petitioned CMS to revise its reimbursement policies for the cardiovascular drug. WLF said CMS is promoting a less expensive generic substitute, even though the Food and Drug Administration has determined that there is no interchangeable product for BiDil.